MOLECULAR MEDICINE CENTER has a total of 27 patent applications. Its first patent ever was published in 1986. It filed its patents most often in Australia, United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, machines and micro-structure and nano-technology are IST FARMACOTERAPICO IT SPA, NABI BIOPHARMACEUTICALS and HSIA JEN CHANG.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 6 | |
#2 | United States | 6 | |
#3 | WIPO (World Intellectual Property Organization) | 6 | |
#4 | EPO (European Patent Office) | 4 | |
#5 | Canada | 2 | |
#6 | Israel | 2 | |
#7 | Ireland | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Machines | |
#3 | Micro-structure and nano-technology | |
#4 | Biotechnology | |
#5 | Computer technology | |
#6 | Measurement |
# | Name | Total Patents |
---|---|---|
#1 | Goldenberg David M | 6 |
#2 | Shih Lisa B | 5 |
#3 | Mattes M Jules | 4 |
#4 | Behr Thomas M | 4 |
#5 | Primus F James | 3 |
#6 | Mattes Michael Jules | 3 |
#7 | Siegel Jeffry Alan | 3 |
#8 | Mattes Michael J | 2 |
#9 | Goldenberg Milton D | 2 |
#10 | Primus Frederick J | 2 |
Publication | Filing date | Title |
---|---|---|
AU2226799A | Antibody/receptor targeting moiety for enhanced delivery of armed ligand | |
WO9529707A1 | Composition for delivery of toxic radioisotopes to the cell nucleus and use | |
US5843894A | Methods for reduced renal uptake of antibody fragments | |
US4846187A | Dual isotope scintigraphic image enhancement | |
US4859449A | Modified antibodies for enhanced hepatocyte clearance | |
US5057313A | Diagnostic and therapeutic antibody conjugates | |
US4699784A | Tumoricidal methotrexate-antibody conjugate |